Takeda seeks 'big data' analytics for rare disease drug discovery
This article was originally published in Scrip
Takeda Development Center Americas – a unit of Takeda Pharmaceutical – is teaming up with big data solutions company BioXcel to research and repurpose assets for use in rare and ultra-rare disease indications.
You may also be interested in...
Public Company Edition: With returns for newly public biopharma companies rising, seven more jumped in line to go public in the US between the beginning of February and early March, while two drug developers launched IPOs in the EU. Meanwhile, already public companies keep raising gobs of cash.
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.